Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness has provided an opportunity to accumulate shares ahead of upcoming catalysts or underappreciated positve factors.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences announces FDA approval of Cologuard Plus test
- Exact Sciences price target raised to $80 from $72 at Evercore ISI
- Exact didn’t get Cologuard Plus price hike in preliminary CLFS, says Wolfe
- Exact Sciences price target raised to $82 from $70 at BTIG
- Canaccord sees colon blood test as attractive revenue stream for Exact